Actively Recruiting
Cardiovascular and Venous Thromboembolism Disease in Patients with Von Willebrand Disease in the French West
Led by University Hospital, Brest · Updated on 2025-02-06
100
Participants Needed
6
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Von Willebrand disease is a common inherited bleeding disorder, and as patients live longer, they face age-related conditions like cancer and heart diseases. This study aims to understand how often blood clots in arteries or veins, and irregular heart rhythms (atrial fibrillation), occur in adults with von Willebrand disease in the western region of France. Researchers want to fill gaps in current knowledge about these events and their management in this population. The study is a retrospective, multicenter observational investigation using data from adult patients with von Willebrand disease who are followed at medical centers in the French West and have experienced thrombotic or cardiovascular events. These events include deep vein thrombosis, pulmonary embolism, stroke, heart attack, limb ischemia, angina, and atrial fibrillation. Information about patient history, treatments like blood thinners or anti-platelet drugs, and complications such as bleeding or recurrence will be collected and analyzed. Participants will have their medical records reviewed to capture details about their von Willebrand disease, risk factors, and treatments related to blood clotting and heart conditions. The study will describe how often these events happen and their types, as well as look at treatment strategies and their tolerance and effectiveness. The research spans 12 months of data review, aiming to provide insights into managing these complex cases safely.
CONDITIONS
Brief Title
Cardiovascular and Venous Thromboembolism Disease in Patients with Von Willebrand Disease in the French West
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with von Willebrand disease
- Adult 18 years or older
- Followed in a reference center in the West of France (Caen, Brest, Nantes, Rennes, Le Mans, Angers)
- Consented to be included in the BERHLINGO database
- Have experienced thrombotic or cardiovascular events such as deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, acute coronary syndrome, acute limb ischemia, angina, obliterating arteriopathy of the lower limbs, or atrial fibrillation
- Have not expressed opposition to participation
You will not qualify if you...
- Have expressed opposition to participation
- Have acquired von Willebrand syndrome
- Are under legal protection
- Are a minor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants who have von Willebrand disease and prior thrombotic or cardiovascular events are observed to describe the frequency and nature of arterial and venous thromboembolic events and atrial fibrillation, along with treatment evaluation.
Data collected retrospectively from medical records; no additional visits required
Trial Site Locations
Total: 6 locations
1
CHU d'Angers
Angers, France, 49933
Not Yet Recruiting
2
CHU de Brest
Brest, France, 29609
Actively Recruiting
3
CHU de Caen
Caen, France, 14033
Not Yet Recruiting
4
CH le MANS
Le Mans, France, 72037
Not Yet Recruiting
5
CHU de Nantes
Nantes, France, 44093
Not Yet Recruiting
6
CHU de Rennes
Rennes, France, 35033
Not Yet Recruiting
Research Team
B
Brigitte PAN PETESCH
S
Sara ROBIN
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here